Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum WELL Health Technologies Corp T.WELL

Alternate Symbol(s):  T.WELL.DB | WHTCF

WELL Health Technologies Corp. is a practitioner-focused digital healthcare company. The Company develops technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. Its business units include Canadian Patient Services, WELL Health USA Patient Services and SaaS and Technology Services. WELL Health USA Patient and... see more

TSX:WELL - Post Discussion

View:
Post by retiredcf on Mar 22, 2023 7:47am

Targets Raised

CIBC World Markets’ Scott Fletcher raised his Well Health Technologies Corp.  target to $7 from $6.50 with an “outperformer” rating, while Canaccord Genuity’s Doug Tyaylor increased his target to $6.50 from $6 with a “buy” rating. The average is $7.92.

“Following WELL’s stronger-than-anticipated Q4 results and outlook, shares traded up 8 per cent Tuesday,” said Mr. Taylor. “The message was that the company would continue to reinvest in high-growth platforms including Circle and WISP, expected to contribute to an overall 17-20-per-cent top-line growth rate in 2023. This means more metered EBITDA expansion, seen up 10 per cent plus year-over-year, given increased investment. We continue to rate WELL a BUY and have increased our target ... we believe the company’s premium valuation on EBITDA is increasingly justified by its record of execution against expectations, its M&A optionality, and that its high-growth assets don’t yet fully contribute mature EBITDA margins.”

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities